<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02424552</url>
  </required_header>
  <id_info>
    <org_study_id>2014-003</org_study_id>
    <secondary_id>2014-002363-15</secondary_id>
    <nct_id>NCT02424552</nct_id>
  </id_info>
  <brief_title>Effect of Vitamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma</brief_title>
  <acronym>EVITA</acronym>
  <official_title>EVITA Trial: Effect of VItamin D as add-on Therapy for Vitamin D Insufficient Patients With Severe Asthma: a Randomized, Double-blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Gutenberg University Mainz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Federal Ministry of Education and Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the EVITA trial is to compare the effects of vitamin D therapy with placebo on
      reducing the dose of inhaled or oral corticosteroids in patients with severe asthma and
      vitamin D insufficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with severe asthma represent the greatest unmet medical need among the asthmatic
      population, in particular due to their high risk of severe exacerbations. A substantial
      proportion of these patients does not achieve asthma control despite even high-dose ICS and
      LABA treatment, necessitating add-on therapy. For these patients oral corticosteroids (OCS)
      are a preferred treatment modality, which will inevitably lead to severe side effects. A high
      Proportion of patients with severe Asthma are Vitamin D insufficient (&lt; 30 ng/ml). It is
      therefore tempting to speculate that vitamin D substitution in vitamin D insufficient
      patients who continue to experience suboptimal asthma control on ICS and LABA or ICS/LABA
      plus OCS treatment may boost corticosteroid responsiveness, thereby potentially reducing
      corticosteroid dose requirements and improving key parameters of asthma control.

      The present study is a multicenter, randomized, double-blind, placebo-controlled study to
      evaluate the efficacy and safety of treatment with vitamin D at a dose of 4000 IU/day
      administered daily following a single loading dose of 100 000 IU upon study entry over a
      period of 24 weeks in patients with severe asthma and vitamin D insufficiency. During the
      study, all patients will remain on their existing maintenance asthma therapy throughout the
      study, in addition to the study treatment, while reducing inhaled or oral steroids according
      to study protocol. The study consists of a 2-week run-in period, a 24 week double-blind
      treatment period including a 12 week steroid stable phase and two steroid reduction phases,
      followed by a follow-up visit 4 weeks after last study medication intake. The active
      treatment arm in this study will be standard of care plus vitamin D (loading dose of 100 000
      IU upon study entry, to be followed by 4000 IU/day for the rest of the study period) while
      the comparator arm will be standard of care plus placebo.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment problems
  </why_stopped>
  <start_date type="Actual">June 26, 2015</start_date>
  <completion_date type="Actual">March 9, 2017</completion_date>
  <primary_completion_date type="Actual">February 9, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>relative dose reduction of ICS or OCS at week 24 as assessed by total ICS or OCS dose</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exacerbations (rate of and time to first and subsequent exacerbations) as assessed by numbers of exacerbations</measure>
    <time_frame>24 weeks and 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Control as assessed by ACQ score</measure>
    <time_frame>at weeks 4, 8, 12, 14, 18, 20, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asthma Quality of Life as assessed by the Mini-AQLQ score</measure>
    <time_frame>at weeks 12, 18, 24 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function test results as assessed by FEV1, FVC, IC, RV, TLC, and airway resistance</measure>
    <time_frame>at weeks 4, 8, 12, 14, 18, 20, 24, and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of vitamin D as assessed by serum concentrations</measure>
    <time_frame>at weeks 12, 18, 24 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients that achieved vitamin D sufficiency</measure>
    <time_frame>at week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of safety and tolerability as assessed by number of adverse events</measure>
    <time_frame>up to 30 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea as assessed by Baseline and Transition Dyspnea Indexes</measure>
    <time_frame>at weeks 12, 18, 24 and 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Amount of Placebo capsules corresponding to initial single dose of Vitamin D3, beginning from the second day amount of capsules corresponding to daily dose of Vitamin D for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3</intervention_name>
    <description>Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.</description>
    <arm_group_label>Vitamin D3</arm_group_label>
    <other_name>Cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Filling material: lactose monohydrate, cellulose, magnesium stearate</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients, age ≥ 18 years

          -  A pulmonary specialist documented diagnosis of severe asthma according to the Global
             Initiative for Asthma and the German Asthma Network (GAN, www.german-asthma-net.de)

          -  Treatment with long-acting β2-agonists (LABA) and inhaled corticosteroids (ICS) at a
             dose of at least 1000 µg beclomethasone (or equivalent) per day, - chronic oral
             corticosteroid (OCS) use is allowed Stable asthma medication for ≥1 month prior to
             screening (≥4 months for omalizumab)

          -  Asthma Control Questionnaire (ACQ-5) score ≥ 1.5

          -  Vitamin D insufficiency as defined by a serum vitamin D concentration of &lt; 30 ng/ml
             but ≥ 10 ng/ml at screening

        Exclusion Criteria:

          -  Patients on vitamin D substitution

          -  Current smokers or ex-smokers with a smoking history of more than 10 pack-years

          -  Pregnant or nursing women or women who intend to become pregnant during the study

          -  Known impaired renal function (GFR &lt; 30 ml/min) and history of physician-diagnosed
             nephrolithiasis

          -  Use of other investigational drugs during the study or within 30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie Korn, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University Mainz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pneumologische Gemeinschaftspraxis Dr. Rolke &amp; Dr. Rückert</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>D-63739</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik III für Pneumologie, allergologie, Schlaf- und Beatmungsmedizin, Berufsgenossenschaftliches Universitätsklinikum Bochum-Bergmannsheil GmbH</name>
      <address>
        <city>Bochum</city>
        <zip>D-44789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKF Pneumologie GmbH &amp; Co.KG</name>
      <address>
        <city>Frankfurt</city>
        <zip>D-60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologisches Forschungsinstitut der LungenClinic Grosshansdorf</name>
      <address>
        <city>Grosshansdorf</city>
        <zip>D-22927</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Studienzentrum KPPK GmbH</name>
      <address>
        <city>Koblenz</city>
        <zip>D-56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KLB - Gesundheitsforschung Lübeck GmbH</name>
      <address>
        <city>Lübeck</city>
        <zip>D-23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologie, III. Medizinische Klinik, Universitätsmedizin der Johannes Gutenberg-Universität Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Innere Medizin II/Pneumologie</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenpraxis Schleswig</name>
      <address>
        <city>Schleswig</city>
        <zip>D-24837</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Korn S, Hübner M, Jung M, Blettner M, Buhl R. Severe and uncontrolled adult asthma is associated with vitamin D insufficiency and deficiency. Respir Res. 2013 Feb 22;14:25. doi: 10.1186/1465-9921-14-25.</citation>
    <PMID>23432854</PMID>
  </reference>
  <reference>
    <citation>Martineau AR, MacLaughlin BD, Hooper RL, Barnes NC, Jolliffe DA, Greiller CL, Kilpin K, McLaughlin D, Fletcher G, Mein CA, Hoti M, Walton R, Grigg J, Timms PM, Rajakulasingam RK, Bhowmik A, Rowe M, Venton TR, Choudhury AB, Simcock DE, Sadique Z, Monteiro WR, Corrigan CJ, Hawrylowicz CM, Griffiths CJ. Double-blind randomised placebo-controlled trial of bolus-dose vitamin D3 supplementation in adults with asthma (ViDiAs). Thorax. 2015 May;70(5):451-7. doi: 10.1136/thoraxjnl-2014-206449. Epub 2015 Feb 27.</citation>
    <PMID>25724847</PMID>
  </reference>
  <reference>
    <citation>Castro M, King TS, Kunselman SJ, Cabana MD, Denlinger L, Holguin F, Kazani SD, Moore WC, Moy J, Sorkness CA, Avila P, Bacharier LB, Bleecker E, Boushey HA, Chmiel J, Fitzpatrick AM, Gentile D, Hundal M, Israel E, Kraft M, Krishnan JA, LaForce C, Lazarus SC, Lemanske R, Lugogo N, Martin RJ, Mauger DT, Naureckas E, Peters SP, Phipatanakul W, Que LG, Sheshadri A, Smith L, Solway J, Sullivan-Vedder L, Sumino K, Wechsler ME, Wenzel S, White SR, Sutherland ER; National Heart, Lung, and Blood Institute’s AsthmaNet. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA. 2014 May;311(20):2083-91. doi: 10.1001/jama.2014.5052.</citation>
    <PMID>24838406</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2015</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>PD Dr. Stephanie Korn</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>vitamin D</keyword>
  <keyword>treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

